

## Hydrogen sulfide and inflammatory-based vascular diseases

M. Bucci, G. Cirino

Dip. di Farmacia, Universita' di Napoli

Hydrogen sulfide (H<sub>2</sub>S) is an endogenous signaling molecule that, together with CO and NO, constitutes the gaseous mediators class defined 'gasotransmitters'. In mammalian cells, H<sub>2</sub>S is produced from L-cysteine through the action of cystathionine beta-synthase (CBS) and cystathionine gamma-lyase (CSE), both pyridoxal-phosphate (PLP) dependent enzymes. There is also a third pathway that involves 3-mercaptopyruvate sulfurtransferase (3-MST) and it is PLP independent. These enzymes are expressed in many tissues and organs: CBS is mainly located within the central nervous system (Kimura 2010), CSE primarily accounts for H<sub>2</sub>S production in the vasculature while (3MST) pathway is emerging in controlling intestinal mucosa physiology (Flannigan et al., 2013). Recent literature clearly shows that H<sub>2</sub>S has a protective action in many pathological conditions, however the mechanism of tissue protection in inflammation is a point of debate. In cardiovascular district, it has been recently demonstrated that H<sub>2</sub>S, either increasing its biosynthesis or administrating it exogenously, attenuates myocardial injury, protects blood vessels, limits vascular inflammation and regulates blood pressure. These pleiotropic actions indicate H<sub>2</sub>S as a critical cardiovascular signaling molecule similar to nitric oxide (NO) and carbon monoxide (CO) with a pivotal role in systemic circulation. In this context, we have investigated on the role of H<sub>2</sub>S in vascular function in both physiological and physio-pathological conditions. In particular, we found reduced levels of tissue and circulating H<sub>2</sub>S in different models of inflammatory-based vascular diseases such as diabetes and SHR-model of hypertension. Starting from these evidences, our studies aimed to evaluate the impact of l-cysteine/CSE /H<sub>2</sub>S pathway in vascular inflammation development and the use of H<sub>2</sub>S-donors as therapeutic agents to ameliorate inflammatory-based vascular dysfunction.